Imaging Neural Correlates of Ketamine Using PET/MR
NCT04587778
Summary
The purpose of this randomized, placebo-controlled study is to investigate pharmacodynamic differences between racemic ketamine and esketamine using functional fluorodeoxyglucose (\[18F\]FDG) positron emission tomography/magnetic resonance imaging (PET/MR) Pilot study I: A pilot study with healthy controls will be performed in order to investigate pharmacokinetic behavior and acute behavioral effects of intravenous ketamine infusion. Pilot study II: A pilot study including 15 healthy volunteers will be performed in order to optimize scanning procedures. The pilot study follows a randomized, placebo-controlled, double-blind, cross-over study design. After enrollment into the study all subjects will undergo two \[18F\]FDG PET/CT scans in the course of which they will receive either S-ketamine or placebo during the first scan and the respective other study medication during the second scan.
Eligibility
Inclusion Criteria: * General health based on medical history, physical examination and structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (SCID) * Age 18 to 55 years * Right-handedness (due to potential lateralization effects of lefthanded subjects) * Willingness and competence to sign the informed consent form. Exclusion Criteria: * Current or history of psychiatric or neurological disease * Current medical illness requiring treatment * Pregnancy or current breastfeeding * Current or former substance abuse * Diagnosis of an Axis-1 psychotic disorder in a first-degree relative * Any contraindication for MRI (e.g., MR incompatible implants, etc.) including dental implants causing signal artifacts * For subjects participating in earlier studies using ionizing radiation, the total radiation exposure of 30 millisievert (mSv) over the last 10 years must not be exceeded, as specified in the Austrian legislation on radiation protection (www.ris.bka.gv.at). Accordingly, body weight \>100kg is an exclusion criterion (5.1 Megabequerel (MBq)/kg \* 100kg \* 0.019 mSv/MBq\* 0.885 = 8.58 mSv per scan, the factor 0.885 is considered due to continuous radioligand infusion, see PET scanning). * Failure to comply with the study protocol or to follow the instruction of the investigating team.
Conditions2
Interventions4
Related trials
- Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia — Second Affiliated Hospital of Wenzhou Medical University
- Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI) — China Medical University, China
- Effect of Low-dose EsketaMine on dElirium in High-risk Elderly Patients uNdergoing elecTive Surgery (ELEMENT) — Nanfang Hospital, Southern Medical University
- Effects of Epidural Labor Analgesia With Esketamine on the Incidence of Postpartum Depression in Parturients — Women's Hospital School Of Medicine Zhejiang University
- Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients — Tianjin Medical University General Hospital
- Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease — Beijing Tiantan Hospital
- Metabolic Profiling of Esketamine Treatment in Depressive Disorder — University of Zagreb
- Personalized DBS Targeting for Treating Depression — Second Affiliated Hospital, School of Medicine, Zhejiang University
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT04587778